News | August 22, 2022
8th edition of Indo-Japanese Chronic Total Occlusion (IJCTO) summit concluded successfully
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Subscribe To Our Newsletter & Stay Updated
